Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1459
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis ; day:8 ; month:2 ; year:2020 ; pages:1-11
Journal of neurology ; (8.2.2020), 1-11
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00415-019-09690-6
- URN
-
urn:nbn:de:101:1-2020050521582915527796
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Schweitzer, F.
- Laurent, S.
- Fink, G. R.
- Barnett, Michael H.
- Hartung, Hans-Peter
- Warnke, C.
- SpringerLink (Online service)
Other Objects (12)
Current Disease-Modifying Therapies in Multiple Sclerosis
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Multiple sclerosis disease-modifying drug use by immigrants: a real-world study
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis
Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis
Current Disease-Modifying Therapies in Multiple Sclerosis
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Multiple sclerosis disease-modifying drug use by immigrants: a real-world study
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis
Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis
Current Disease-Modifying Therapies in Multiple Sclerosis
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Multiple sclerosis disease-modifying drug use by immigrants: a real-world study
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis